In a report published Wednesday, Aegis Capital Corp. initiated coverage on Sinovac Biotech Ltd. SVA with a Hold rating and $2.50 price target.
Aegis Capital noted, “We are initiating coverage of Sinovac Biotech Ltd. (NASDAQ/SVA) with a Hold rating and a 12-month price target of $2.50 per share. While we note that the firm is operating in a traditionally high-growth arena - vaccine production - and is primarily targeting China, which has been among the fastest-growing vaccine markets of late, the vaccines business is cyclical and the firm has recently suffered from a weak influenza season and decreased public market sales. We expect to remain neutral on the name until evidence of sustainable sales growth and a return to profitability can be conclusively demonstrated.”
Sinovac Biotech Ltd. closed on Tuesday at $2.52.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in